Proof of concept in preclinical models for the use of QPCTL inhibition

Two independent studies were published this week on Scenic’s inflammation drug target QPCTL. The studies were conducted by Genentech and Scenic’s SAB member Ton Schumacher at the Netherlands Cancer Institute. The publications provide proof of concept in preclinical models for the use of QPCTL inhibition in combination with other checkpoint inhibitors for the treatment of solid tumours.